Microbiomes are responsible for a wide variety of metabolic and developmental processes—from food digestion to vitamin synthesis and even brain function. They also play a major role in human conditions, such as obesity and inflammatory bowel disease.
This market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5 % during the forecast period.
The therapeutics segment to account for the largest share of the market in 2022
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2022. This is due to the need for the development of reliable, precise, and quicker treatment of chronic lifestyle diseases and various other disorders.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
The infectious diseases segment to account for the largest share of the market in 2022
Based on disease, the human microbiome market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.
Recent Developments:
# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.
# In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn’s disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.
# In 2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.
Europe to account for the largest share of the human microbiome market in 2022
On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.
Key questions addressed by the report:
# Who are the major market players in the human microbiome market?
# What are the regional growth trends and the largest revenue-generating regions for the market?
# What are the major drivers and challenges in the market?
# What are the major product segments in the market?
# What are the major technologies used in the human microbiome research spending market?
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
Global Industry Leaders:
The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US). Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.
